Skip to main content

Search articles in Pharmaceuticals

Found 661 articles

  • With Once-a-Week Dosing, Insulin Efsitora Alfa Del

    With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

    • 17 May 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections.

  • GSK to become a founding partner of Fleming Initia

    GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)

    • 16 May 2024
    • Editor

    Global biopharmaceutical company, GSK, will become the first founding partner of the Fleming Initiative, an innovative and collaborative approach led by Imperial College Healthcare NHS Trust and Imperial College London to tackle antimicrobial resistance (AMR) around the world.

  • Baxter Announces Mission and Logo for Proposed Kid

    Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive

    • 16 May 2024
    • Editor

    Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.

  • AC Immune and Takeda Sign Exclusive Option and Lic

    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

    • 14 May 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.

  • Top 6 Pharmaceutical Companies in the UK 2024

    Top 6 Pharmaceutical Companies in the UK 2024

    • 30 Apr 2024
    • Lucy Walters

    In 2024, the pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry.

  • FDA Grants Full Approval for TIVDAK® to Treat Recu

    FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

    • 30 Apr 2024
    • Editor

    Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

  • Voydeya approved in the EU as add-on treatment to

    Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

    • 24 Apr 2024
    • Editor

    Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.

  • Lilly Acquires New Injectable Medicine Manufacturi

    Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals

    • 23 Apr 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.

  • Takeda Recognized with 2024 ISPE Facility of the Y

    Takeda Recognized with 2024 ISPE Facility of the Year Awards in Category Operations

    • 17 Apr 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the category Operations with the 2024 Facility of the Year Awards (FOYA).

  • Fresenius Accelerates Momentum in its (Bio)Pharma

    Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.

    • 16 Apr 2024
    • Editor

    Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra®** (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.

  • Vertex Enters Into Agreement to Acquire Alpine Imm

    Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

    • 11 Apr 2024
    • Editor

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

  • Enhertu approved in the US as first tumour-agnosti

    Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours

    • 8 Apr 2024
    • Editor

    AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.

  • AstraZeneca to acquire Amolyt Pharma, expanding la

    AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

    • 14 Mar 2024
    • Editor

    AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.

  • About MorphoSys

    About MorphoSys

    • 8 Mar 2024
    • Editor

    At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated.

  • Aston Pharmacy School students benefit from genera

    Aston Pharmacy School students benefit from generative AI simulation to prepare them for the real world

    • 29 Feb 2024
    • Editor

    Aston Pharmacy School has introduced new generative artificial intelligence (AI) simulation software to train students in common situations they will encounter in practice and ensure they are properly prepared for their pharmacy placements.

  • U.S. FDA Approves Expanded Indication for Gilead’s

    U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

    • 27 Feb 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.

  • Voydeya recommended for approval in the EU by CHMP

    Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia

    • 27 Feb 2024
    • Editor

    Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.

  • European Commission Approves Pfizer’s VELSIPITY® f

    European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

    • 20 Feb 2024
    • Editor

    Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

  • Tagrisso with the addition of chemotherapy approve

    Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

    • 20 Feb 2024
    • Editor

    Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care. AstraZeneca’s has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

  • Top 10 Pharmaceutical Companies in Australia 2024

    Top 10 Pharmaceutical Companies in Australia 2024

    • 14 Feb 2024
    • Lucy Walters

    Revenue in Australia’s pharmaceuticals market is projected to reach US$10.16bn in 2024, with the largest market being Oncology Drugs with a projected market volume of US$2.01bn. This revenue is expected to grow at an annual rate of 6.76% from 2024 to 2028, resulting in a market volume of US$13.20bn by 2028.